Brak połączenia z internetem — wyświetlanie zapisanej wersji strony.

Mesoblast Ltd

USUSD
← Do screenera
US:MEOBFAU:MSB

Mesoblast Ltd (AU:MSB) — Biotechnology: Biological Products (No Diagnostic Substances). Liczba giełd, na których notowane są akcje spółki: 2. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.

O firmie

Strona
mesoblast.com
Sektor
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
Siedziba
MELBOURNE, VICTORIA, Australia
Prezes
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons)
Pracownicy
108
Akcje w obrocie
1.3 mld na 2026-06-30
Free float
861.1 mln
Kapitalizacja rynkowa
1.48 mld USD
Insiderzy
36.28%
Inwestorzy instytucjonalni
17.44%
Branża (SIC)
Biological Products, (No Diagnostic Substances)
ISIN
AU000000MSB8
Opis

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenne muscular dystrophy, and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease; and Revascor for the treatment of hypoplastic left heart syndrome. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; MPC-150-IM for the treatment or prevention of chronic heart failure; Ryoncil for the treatment of pediatric SR-aGVHD; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM; Grünenthal GmbH to develop and commercialize MPC-06-ID for the treatment of chronic low back pain due to degenerative disc disease in patients; and JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.

Giełdy i tickery

GiełdaTickerWalutaCenaTyp
US USA StocksMEOBF OTCUSD1.39 +21.93%akcje zwykłe
AU Australian Securities ExchangeMSB główneAUD—akcje zwykłe

Cena z 3 miesięcy

dzień wzrostu dzień spadku dzień ex-dywidendy dzień wypłatyNajedź / dotknij dnia — ceny otwarcia, zamknięcia, najwyższa i najniższa

Dywidendy

Nie znaleziono wypłat dywidend (sprawdzono 08.10.2026). Firma prawdopodobnie nie wypłaca dywidend.

Wiadomości w tym tygodniu

Brak jeszcze wiadomości ze strony spółki.

reklama

Najwięksi akcjonariusze

PosiadaczUdziałAkcjeData raportu
Itescu (Silviu) (Chief E…≈6.23%80.84 mln2026-07-17
VANGUARD STAR FUNDS-Vang…1.05%13.66 mln2026-04-30
VANGUARD TAX-MANAGED FUN…0.62%8.01 mln2026-06-30
iShares Trust-iShares Co…0.53%6.88 mln2026-07-31
Rose (Eric) (Director (N…≈0.52%6.75 mln2026-01-09
DFA INVESTMENT TRUST CO-…0.36%4.68 mln2026-04-30
VANGUARD Intl Eqy. INDEX…0.27%3.51 mln2026-04-30
iShares Trust-iShares MS…0.24%3.07 mln2026-07-31
SCHWAB STRATEGIC TRUST-S…0.15%1.99 mln2026-05-31
Dimensional ETF Trust-Di…0.11%1.38 mln2026-04-30
iShares Trust-iShares Co…0.09%1.23 mln2026-07-31
SPDR INDEX SHARES Fd.S-S…0.09%1.19 mln2026-08-31
Bell (Jane Catherine) (D…≈0.05%622 4922025-02-28
Burns (William) (Indepen…≈0.02%226 2502025-10-21
Legato Capital Managemen…0.01%47 3802022-06-30
Cobley (Lyn Elizabeth) (…≈0%63 0002026-01-09